Chronischer Schmerz
Studienlage · Detail Leitlinie · Chronischer Schmerz · 2025

Cannabis or Cannabinoids for the Management of Chronic Noncancer Pain: Best Practice Advice From the American College of Physicians.

Unklar 12 Zitate
StichprobeLeitlinie
Dauerunklar
EndpunktNutzen-Schaden-Abwägung
Verblindungn.a.
DesignLeitlinie
Kernaussage

Leitlinie empfiehlt selektive Beratung über Nutzen und Schäden von Cannabis/Cannabinoiden bei chronischen Nicht-Krebs-Schmerzen; warnt vor Schaden bei spezifischen Subgruppen.

Zusammenfassung

Best Practice Advice des American College of Physicians zu Cannabis/Cannabinoiden bei chronischem Nicht-Tumorschmerz. Basierend auf Living Systematic Reviews. Empfehlungen: Nutzen-Risiko-Aufklärung für alle Patienten; Risiko überwiegt Nutzen bei Adoleszenten, Substanzgebrauchsstörung-Anamnese, schwerer psychischer Erkrankung, Sturzrisiko; Kontraindikation in Schwangerschaft/Stillzeit; Abraten von inhalativem Cannabis.

P
PopulationErwachsene mit chronischem nicht-krebsbedingtem Schmerz (chronischer Nicht-Tumor-Schmerz)
I
InterventionCannabis oder Cannabinoide (verschiedene Applikationsformen)
O
OutcomeLeitlinienempfehlungen: Nutzen-Schaden-Abwägung; Beratungspflicht; Abraten bei Schwangerschaft, Stillzeit, Jugendlichen, Suchterkrankung, schwerer psychischer Erkrankung und Inhalationsroute
Qualitätsprofil
Größe
Verblindung
Effektstärke
Zitate / Jahr
Autoren
Kansagara D, Hill KP, Yost J, Humphrey LL, Shaw B, Obley AJ, Haeme R, Akl EA, Qaseem A, Dunn AS
DOI 10.7326/annals-24-03319
Design: Leitlinie
Teilen
Abstract
Description: The American College of Physicians' Population Health and Medical Science Committee (PHMSC) developed this best practice advice to inform clinicians about what is currently known about the benefits and harms of cannabis or cannabinoids in the management of chronic noncancer pain and to provide advice for clinicians counseling patients seeking this therapy. Methods: The PHMSC considers areas where evidence is uncertain or emerging or practice does not follow the evidence to provide clinical advice based on a review and assessment of scientific work, including systematic reviews and individual studies. Sources of evidence included a living systematic review on cannabis and cannabinoid treatments for chronic noncancer pain and a series of living systematic reviews and primary studies. BEST PRACTICE ADVICE 1A: Clinicians should counsel patients about the benefits and harms of cannabis or cannabinoids when patients are considering whether to start or continue to use cannabis or cannabinoids to manage their chronic noncancer pain. BEST PRACTICE ADVICE 1B: Clinicians should counsel the following subgroups of patients that the harms of cannabis or cannabinoid use for chronic noncancer pain are likely to outweigh the benefits: young adult and adolescent patients, patients with current or past substance use disorder, patients with serious mental illness, and frail patients and those at risk for falling. BEST PRACTICE ADVICE 2: Clinicians should advise against starting or continuing to use cannabis or cannabinoids to manage chronic noncancer pain in patients who are pregnant or breastfeeding or actively trying to conceive. BEST PRACTICE ADVICE 3: Clinicians should advise patients against the use of inhaled cannabis to manage chronic noncancer pain.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel